INTRODUCTION

Colorectal cancer is the second most common cancer in the United States, and third most common cancer in Korea.¹,² Therefore, diverse strategies for treatment of colorectal cancer continue to be developed. Rectal cancer treatment varies depending on various characteristics, particularly by stage of cancer.³ The standard treatment for early rectal cancer is removal by local excision.⁴,⁵ However, there has been a recent trend toward chemoradiotherapy followed by excision for early rectal cancer. When a complete response is confirmed through chemoradiotherapy, a “watch and wait” approach is used without additional surgical treatment. Conversely, in advanced rectal cancer, radical surgery is performed depending on the location of the tumor or metastasis to lymph nodes (LNs).⁶ In advanced rectal cancer, neoadjuvant chemoradiotherapy decreases cancer stage, facilitates a secure circumferential margin through reduction in the size of the cancer, increases the likelihood of preservation of the anal sphincter, and reduces the probability of recurrence.⁷,⁸ However, radical surgery for low rectal cancer can lead to permanent stoma, increased mortality and morbidity, decreased quality of life, and increased disability.⁹,¹⁰ Therefore, it is important to determine the risk factors that affect survival after local excision of rectal cancer and develop strategies to improve outcomes.
ly, radical surgery should be avoided, and local excision should be performed. Local excision has advantages of decreased operation time and hospitalization period, reduced likelihood of permanent stoma, and reduced mobility. Despite these advantages, there are many risk factors associated with choosing local excision over radical operation. Failure to identify and treat hidden LN metastasis and failure to obtain an adequate safety margin during tumor resection can affect patient staging, leading to inappropriate treatment. As a result, the recurrence rate increases and overall survival decreases. When rectal cancer recurs, disease management becomes much more difficult, and more extensive resection is required. However, when recurrence occurs after local excision of rectal cancer, it remains unclear which treatment will most benefit patients. For this reason, the indications for local excision of rectal cancer remain controversial. The purpose of this study was to investigate factors affecting survival rate and recurrence after local excision in rectal cancer patients and differences between non-salvage treatment and salvage operation in cases of recurrence.

**MATERIALS AND METHODS**

**Patients**
A total of 831 records of patients with rectal cancer who were treated with local excision from January 2000 to December 2015 at a tertiary university hospital were reviewed retrospectively (Fig. 1). All patients participating in the study underwent preoperative abdominoperineal CT and pelvic MRI to determine clinical stage. Inclusion criteria were 18 years of age or older, diagnosis with local excision of rectal adenocarcinoma 15 cm above the anal verge, and absence of exclusion. We excluded patients who had recurrence at the time of local excision, distant metastasis, genetic disorders, synchronous malignancy, or palliative surgery. A total of 391 eligible patients was classified according to these criteria. Fifty-eight patients received neoadjuvant concurrent chemoradiotherapy (CCRT). The remaining 333 patients underwent surgery without CCRT because of the absence of suspected LN metastasis. Our criteria for preoperative CCRT in rectal cancer were clinical suspicion of T3 or T4 rectal cancer or suspected LN metastasis in the perirectal area on MRI. The 58 patients who underwent neoadjuvant chemoradiotherapy received fluorouracil-based chemotherapy. Surgery was performed at 6 to 8 weeks after preoperative CCRT. Patients from clinical T stages 1 to 3 were included. Patients in clinical stage 3 who underwent local excision were provided sufficient information on the course of rectal cancer and treatment guidelines.

All operations comprised full-thickness excision of the rectal wall, and the excision site was closed with sutures. Local excision was performed with two surgical techniques: transanal excision (TAE) and transanal endoscopic microsurgery (TEM). Samsung Medical Center’s Institutional Review Board approved this study’s use of information obtained from patient records (IRB No: 2019-04-041).

**Recurrence**
All patients who participated in this study underwent a 5-year surveillance program. Patients were followed every 3 months for the first 2 years and then every 6 months for 3 years thereafter. During the follow-up period, cancer recurrence was
monitored through various tests, such as physical examination; serum carcinoembryonic antigen (CEA) level; chest X-ray; and abdominal, pelvic, and chest CT. Recurrence of cancer was confirmed pathologically by biopsy in patients suspected of recurrence or confirmed by CT scan, MRI, or positron emission tomography CT scan.

Recurrence was classified as local recurrence (LR), systemic recurrence (SR), or combined recurrence (CR). LR was defined as intra-pelvic recurrence following primary rectal cancer resection, without distant metastasis. SR was defined as recurrence only in other organs without LR. CR was defined as local and distant metastasis during the follow-up period.

Statistical analysis
Statistical analysis was performed using SPSS for Windows (version 25.0; IBM Corp., Armonk, NY, USA). Patient characteristics were described by Student’s t test, chi-square test, and Fisher’s exact test. Variables with a p<0.1 according to univariate analysis were further analyzed using the Cox regression method for multivariate analysis. Disease-free survival and overall survival rates were determined using Kaplan-Meier analysis and log-rank test. Statistical significance was defined as a p<0.05.

RESULTS
Patient characteristics
Of 391 patients, 211 male (54.0%) and 180 female (46.0%) were enrolled in this study. Mean age was 58.99±11.33 years (range, 28–87 years). Mean body mass index was 24.32±3.05 kg/m². Mean tumor distance from the anal verge was 5.40±2.92 cm, and mean tumor size was 1.68±1.21 cm. Mean preoperative CEA level was 1.90±2.81 ng/mL. With regard to postoperative pathologic T stage, there were 345 patients with T1, 39 patients with T2, and 7 patients with T3 stage disease. Mean duration of follow-up was 75.74±47.69 months (range, 3–223 months). Fifty-one patients (13.5%) underwent local excision by TAE, 338 patients (86.4%) by TEM, and 2 patients (0.1%) by transanal minimally invasive surgery. Baseline characteristics of the patients were classified according to preoperative CCRT. For clinical T stage, the stages at preoperative CCRT and re-diagnosis by MRI were included. Between control and CCRT groups, there were statistical differences in American Society of Anesthesiology score, distance from the anal verge, clinical T stage, tumor size, cell type, pathologic T stage, and TNM stage. The clinicopathologic features of patients are summarized in Table 1.

After local excision, recurrence was observed in 45 patients (11.5%; 45/391). When classified by pathologic T stage, recurrence affected 32 patients in stage T0–T1, 11 in T2, and 2 in T3. A total of 20 patients experienced LR in the pelvis and anastomosis sites regardless of SR (5.1%; 20/391). Those with only distant metastasis (systemic metastasis) represented 5.3% (21 patients) of the sample. There were four cases of CR with both local and distant metastases. Recurrence was most common in the second year after surgery (Fig. 2), but occurred up to 92 months after local excision. When the overall survival rate of patients was analyzed in relation to recurrence, the 5-year survival rates were 94.4% for the non-recurrence group and 66.8% for the recurrence group (Fig. 3).

Univariate analysis and multivariate analyses were performed to identify factors that impacted disease-free survival after local excision of rectal cancer (Table 2). Ninety percent profile likelihood confidence intervals were calculated for hazard ratios. Age (p=0.021), preoperative CCRT (p=0.01), distance from the anal verge (p=0.003), and histologic grade (p=0.045) influenced prognosis on univariate analysis. Multivariate analysis identified distance from the anal verge (p=0.038) and histologic grade (p=0.047) as factors influencing prognosis. We also used univariate analysis to identify factors that affected overall survival after local excision of rectal cancer (Table 3). At a hazard ratio of 90%, age (p<0.001), preoperative CEA (p=0.001), distance from the anal verge (p=0.036), and histologic grade (p=0.028) affected prognosis. Multivariate analysis revealed an association of prognosis with age (p<0.001), preoperative CEA (p<0.001), and histologic grade (p<0.013).

We classified and analyzed relapsed patients according to CCRT status. Of the 58 patients who underwent preoperative CCRT, 13 experienced recurrence. Eight exhibited LR, four SR, and one CR. All 8 patients with LR underwent additional operations, comprising six abdominopelvic resections and two low anterior resections. Of the 4 patients with SR, two refused additional treatment and died. One refused further treatment because another cancer was found and died. The last patient with SR underwent additional chemoradiotherapy and is alive. The CR patient refused both surgery and chemoradiotherapy and died without additional treatment. Of the 351 patients who did not receive preoperative CCRT, 32 exhibited recurrence: 12 LR, 17 SR, and three CR. Of the patients with LR, 10 underwent additional surgery of one abdominoperineal resection, one intersphincteric resection, one Hartmann operation, four low anterior resections, and two local excisions. Of the 17 SR patients, eight had liver metastasis, seven had lung metastasis, and two had multiple metastases. Among these patients, five received postoperative CCRT, five received chemotherapy, and one received radiotherapy only. Six patients underwent surgical treatment for metastasis without additional chemotherapy. Three of these patients showed CR, two refused additional treatment, and only one patient underwent low anterior resection and chemoradiotherapy.

During this study, seven patients were diagnosed with T3 stage disease after local excision. Five patients underwent additional salvage operation, but two refused further surgery. Of the seven T3 patients, three died. Of these, two refused surgery and one underwent additional salvage operation, but systemic
### Table 1. Clinicopathologic Features of the Study Patients (n=391)

|                  | Preop CCRT (-) (n=333) | Preop CCRT (+) (n=58) | Total (n=391) | \( p \) value |
|------------------|-------------------------|------------------------|---------------|--------------|
| **Age (yr)**     |                         |                        |               |              |
| <64              | 228 (68.5)              | 33 (56.9)              | 261 (66.8)    |              |
| ≥65              | 105 (31.5)              | 25 (43.1)              | 130 (33.2)    | 0.084        |
| **Sex**          |                         |                        |               | 0.627        |
| Male             | 178 (53.5)              | 33 (56.9)              | 211 (54.0)    |              |
| Female           | 155 (46.5)              | 25 (43.1)              | 180 (46.0)    |              |
| **Preoperative CEA level (ng/mL)** | 1.84±2.51              | 2.17±4.18              | 1.90±2.81     | 0.058        |
| 0–5              | 303 (98.1)              | 51 (96.2)              | 354 (97.8)    | 0.402        |
| ≥5               | 6 (1.9)                 | 2 (3.8)                | 8 (2.2)       |              |
| **BMI (kg/m\(^2\))** | 24.29±2.95             | 24.41±3.56             | 24.32±3.05    | 0.054        |
| **ASA score**    |                         |                        |               |              |
| I                | 170 (51.1)              | 19 (32.8)              | 189 (48.3)    | 0.035        |
| II               | 148 (44.4)              | 36 (62.1)              | 184 (47.4)    |              |
| III              | 15 (4.5)                | 3 (5.2)                | 18 (4.6)      |              |
| **Anal verge (DRE) (cm)** | 5.71±2.93              | 3.61±2.14              | 5.4±2.92      | 0.004        |
| <4               | 82 (24.6)               | 33 (56.9)              | 115 (29.4)    | <0.001       |
| ≥4               | 251 (75.6)              | 25 (43.1)              | 276 (70.6)    |              |
| **Clinical T stage** |                     |                        |               | <0.001       |
| T1               | 310 (93.1)              | 21 (36.2)              | 332 (84.9)    |              |
| T2               | 21 (6.3)                | 13 (22.4)              | 33 (8.4)      |              |
| T3               | 2 (0.6)                 | 24 (41.4)              | 26 (6.6)      |              |
| **Tumor size (cm)** | 1.77±1.25              | 1.11±0.80              | 1.68±1.21     | 0.045        |
| <2               | 215 (64.6)              | 49 (84.5)              | 264 (67.5)    | 0.003        |
| ≥2               | 118 (35.4)              | 9 (15.5)               | 127 (32.5)    |              |
| **Histologic grade** |                     |                        |               | <0.001       |
| WD               | 220 (66.1)              | 23 (39.7)              | 243 (62.1)    |              |
| MD               | 102 (30.6)              | 34 (58.6)              | 136 (34.8)    |              |
| PD               | 9 (2.7)                 | 0                      | 9 (2.3)       |              |
| MUC              | 2 (0.6)                 | 1 (1.7)                | 3 (0.8)       |              |
| **Pathologic T stage** |                  |                        |               | <0.001       |
| T0, Tx, T1/yT0, yT1 | 303 (91.0)              | 42 (72.4)              | 345 (88.2)    |              |
| T2/yT2           | 27 (8.1)                | 12 (20.7)              | 39 (10.0)     |              |
| T3/yT3           | 3 (0.9)                 | 6 (9.6)                | 7 (1.8)       |              |
| **TNM stage**    |                         |                        |               | 0.001        |
| Stage I          | 330 (99.1)              | 53 (91.4)              | 383 (98)      |              |
| Stage II         | 2 (0.6)                 | 3 (5.2)                | 5 (1.3)       |              |
| Stage III        | 1 (0.3)                 | 2 (3.4)                | 3 (0.8)       |              |
| **CRM**          |                         |                        |               | 0.162        |
| Negative         | 312 (93.7)              | 57 (98.3)              | 369 (94.4)    |              |
| Positive         | 21 (6.3)                | 1 (1.7)                | 22 (5.6)      |              |
| **Lymphovascular invasion** |               |                        |               | 0.006        |
| Negative         | 191 (57.4)              | 29 (50.0)              | 220 (56.3)    |              |
| Positive         | 40 (12.0)               | 1 (1.7)                | 41 (10.5)     |              |
| Undescribed      | 102 (30.6)              | 28 (48.3)              | 130 (33.2)    |              |
| **Perineural invasion** |                  |                        |               | 0.413        |
| Negative         | 133 (39.9)              | 19 (32.8)              | 152 (38.9)    |              |
| Positive         | 2 (0.6)                 | 1 (1.7)                | 3 (0.8)       |              |
| Undescribed      | 198 (59.5)              | 38 (65.5)              | 236 (60.4)    |              |
metastasis progressed and they died (Table 4).

In subgroup analysis of patients with recurrence, 25 underwent reoperation and 20 did not. There was a significant difference in 5-year overall survival rate between these individuals (84.7%, reoperation group; 44.2%, non-operation group; *p* < 0.001) (Fig. 4). The characteristics of recurrence with salvage operation patients are described in Table 5.

Complications occurred in 15 patients (3.6%), and major complications occurred in 5 (1.2%). In 2 patients, perforation occurred at the operation site, 2 patients had intraluminal bleeding, and 1 patient developed a rectovaginal fistula. There was no postoperative mortality. The circumferential resection margin was positive in 5.6% of patients (22), four of whom exhibited recurrence.

**DISCUSSION**

Therapeutic strategies for rectal cancer are evolving in various ways. Until recently, radical surgery was the best option for rectal cancer. However, with the development of chemotherapy, local excision using new techniques, and the latest diagnostic techniques, strategies for treating cancer without salvage operations are increasing. According to this trend, many researchers are conducting “watch and wait” studies to observe patients without surgery. However, the treatment of choice for advanced rectal cancer is still a radical operation, encompassing low anterior resection or abdominopelvic resection, and recurrence rates have decreased with radical surgery. However, complications caused by radical surgery and increased morbidity and mortality are larger disadvantages, compared to the patient advantages. While surgery improves oncologic outcomes, uncertainty exists around patient toleration of complications or dysfunction. In order to minimize damage to patients, continuing research seeks to avoid radical operations and to perform local excision. Although more studies on local excision have been performed, there have not been many studies on recurrent disease after local excision or the prognostic factors that affect recurrence.

After local excision, 22 patients (5.6%) were circumferential resection margin positive, and the total number of recurrence patients was 45 (11.5%). This recurrence rate is relatively low,
compared to that in previous studies. However, according to the results of recent studies, the recurrence rate after local excision is decreasing. In a study of Suzuki, et al., the recurrence rate after local excision of CCRT for early rectal cancer was 8% (4/50). In addition, Sun, et al. reported that the recurrence rate for rectal cancer when TAE was performed was 13.8% (16/116). According to the results of van Oostendorp, et al., a recent meta-analysis study on local excision of rectal cancer, the recurrence rate of patients who underwent local resection alone was 13.6%. In our study, stage T1 patients accounted for the majority (93%), and patients who underwent CCRT before surgery were included and showed a low recurrence rate. In a study by Xu, et al., prognostic factors associated with a high risk of recurrence after radical operation in colorectal cancer were poor differentiation, old age, lymphovascular permeation, and perineural invasion. Saso, et al. found that CEA level, preoperative obstruction, tumor invasion, lymphatic invasion, and venous invasion were correlated with disease-free survival. A study by Ryuk, et al. found that CA19-9 level, venous invasion, and advanced N stage affected recurrence within 2 years after curative resection for colorectal cancer. In our study, distance from the anal verge and histologic grade were found to affect recurrence.

Recurrence after preoperative CCRT occurred in 13 of 58 patients (22.4%). This is more than double the probability of recurrence in patients without CCRT [32/333 (9.6%)]. However, patients treated with preoperative CCRT were diagnosed at a higher stage than other patients and were downstaged through CCRT. In addition, when comparing the pathologic T stage, more than twice the proportion of patients were diagnosed with T2–T3 stage out of the CCRT group (Table 1). It is thought
Factors affecting overall survival after local excision were investigated. Age, preoperative CEA level, and histologic grade were significantly different between groups. Several studies have shown that prognostic factors, such as pathologic T stage, affect survival. However, our study did not show any significant results for pathologic T stage. This might be due to the small number of patients.

In this study, patients diagnosed with clinical stage T3 who underwent local excision were included (Table 6). In cases of stage T3, salvage operation met treatment guidelines but was not performed. Prior to surgery, sufficient data were provided to all patients, and the need for treatment was explained. However, only local excision was performed due to the burden of stoma formation, fear of postoperative complication, economic burden, and difficulty in anesthesia due to underlying dis-

### Table 3. Univariate and Multivariate Analyses of Prognostic Factors Affecting Overall Survival after Local Excision of Rectal Cancer

| Variable                | Univariate analysis |           | Multivariate analysis |           |
|-------------------------|---------------------|-----------|-----------------------|-----------|
|                         | HR (90% CI)         | p value   | HR (95% CI)           | p value   |
| Age                     | <65 yr vs. ≥65 yr   | 4.724 (2.674–8.344) | <0.001                | 3.729 (1.997–6.962) | <0.001 |
| Sex                     | Male vs. Female     | 1.135 (0.664–1.939) | 0.644                 |
| Preop CEA               | <5 ng/mL vs. ≥5 ng/mL | 4.579 (1.795–11.679) | 0.001                | 5.020 (1.895–13.297) | 0.001 |
| Preop CCRT              | No vs. Yes          | 0.630 (0.269–1.475) | 0.287                 |
| Tumor size              | <2 cm vs. ≥2 cm     | 0.983 (0.557–1.736) | 0.953                 |
| Anal verge              | <4 cm vs. ≥4 cm     | 0.561 (0.327–0.964) | 0.036                | 0.598 (0.320–1.114) | 0.105 |
| Pathologic T stage      | Tx, T0, T1, T2 vs. T3 | 1.801 (0.438–7.409) | 0.415                |
| Histologic grade        | WD, MD vs. PD, MUC  | 2.812 (1.117–7.078) | 0.028                | 3.750 (1.324–10.625) | 0.013 |
| CRM                     | No vs. Yes          | 1.311 (0.473–3.638) | 0.603                 |
| Lymphatic invasion      | No vs. Yes          | 1.153 (0.437–3.040) | 0.774                 |
| Perineural invasion     | No vs. Yes          | 0.305 (0.040–2.329) | 0.252                 |
| Vascular invasion       | No vs. Yes          | 1.698 (0.595–4.845) | 0.322                 |
| Tumor budding           | No vs. Yes          | 0.268 (0.060–1.197) | 0.084                 |

WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; MUC, mucinous carcinoma; CCRT, concurrent chemoradiotherapy; CEA, carcinoembryonic antigen; CRM, circumferential resection margin; HR, hazard ratio; CI, confidence interval.

### Table 4. Initial Pathology of Patients with Recurrence

| Pathology | LR | SR | CR | Reoperation |
|-----------|----|----|----|-------------|
| pT0, pTx  | 8  | 2  | -  | 7           |
| pT1       | 9  | 10 | 3  | 12          |
| pT2       | 3  | 8  | 0  | 5           |
| pT3       | -  | 1  | 1  | 1           |
| Total     | 20 | 21 | 4  | 25          |

LR, local recurrence; SR, systemic recurrence; CR, combined recurrence.

that this rate also affected the recurrence rate.

Factors affecting overall survival after local excision were investigated. Age, preoperative CEA level, and histologic grade were significantly different between groups. Several studies have shown that prognostic factors, such as pathologic T stage, affect survival. However, our study did not show any significant results for pathologic T stage. This might be due to the small number of patients.

In this study, patients diagnosed with clinical stage T3 who underwent local excision were included (Table 6). In cases of stage T3, salvage operation met treatment guidelines but was not performed. Prior to surgery, sufficient data were provided to all patients, and the need for treatment was explained. However, only local excision was performed due to the burden of stoma formation, fear of postoperative complication, economic burden, and difficulty in anesthesia due to underlying dis-

![Fig. 4. Five-year overall survival in patients who were treated for recurrence after local excision. The overall survival rate was 84.7% (n=25) in the salvage operation group and 44.2% (n=20) in the non-salvage group (p<0.001; log-rank test).](https://doi.org/10.3349/ymj.2021.62.12.1107)
ease. It is necessary to investigate the prognosis of local resection in T3 patients.

We mainly recommended salvage operation in cases of LR. However, local excision was repeated based on patient desire or refusal of salvage operation. In cases of combined metastasis, chemotherapy was performed as the first treatment, but local excision was not performed with disease progression. Finally, there have been cases of refusal of further treatment in old age or economically poor patients.

LR after 5 years is uncommon but has been reported. In our study, 5 patients relapsed, four of whom were identified with pathologic T1 and one with pathologic T2. All 5 patients underwent adjuvant CCRT after local excision. In view of these results, tumor regression due to chemotherapy is not confirmed or is considered to be delayed in diagnosis due to slow tumor regrowth.

There were several limitations to this study. Our study was performed retrospectively at a single institution. Local excision of rectal cancer was performed using two techniques, and the difference between the two techniques might have influenced outcomes. Tumor stage could not be identified in greater detail, preventing comparison of stage 1 and stage 2 disease in relation to LN metastasis. However, it is difficult to obtain sufficient information on node metastasis in patients who underwent local excision only. Additional pathologic reports were not obtained for all patients. Tumor budding, lymphovascular invasion, perineural invasion, and lymphatic invasion were screened selectively before 2005, after which data often were missing.

Patients who underwent local excision for rectal cancer were reviewed, and the recurrence rate was 11.5%. The prognostic factors affecting recurrence after local excision were distance from the anal verge and histologic grade. Prognostic factors affecting overall survival were age, preoperative CEA, and histologic grade. The survival rate was higher among patients who underwent additional surgery at recurrence than among those who underwent chemotherapy or radiotherapy.

| Table 5. Characteristics of Recurrence among Salvage Operation Patients (n=25) |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| Age (range), yr             | 61.72 (31–81)              | Sex                         | Male                        | 14 (56)                     | Female                      | 11 (44)                     | Mean prep CEA (ng/mL)       | 3.23±6.58                   | BMI (kg/m²)                 | 24.02±2.62                  | ASA score                   | I                           | 8 (32)                     | II                          | 17 (68)                     | III                         | 0                           | Mean tumor diameter (cm)    | 1.90±1.58                   | Mean distance from anal verge (DRE) | 5.26±4.63               |
| Pathologic T stage          |                            |                             |                            |                            |                            |                            | pT1                         | 3 (12)                      | pT2                         | 3 (12)                      | pT3                         | 12 (48)                     |
| Histology                   |                            |                             |                            |                            |                            |                            | WD                          | 2 (8)                       | MD                          | 12 (48)                     | PD                          | 2 (8)                       | MUC                         | 1 (4)                       | No residual tumor           | 6 (24)                      | Lymphovascular invasion positive | 4 (16)                      | Perineural invasion positive | 3 (12)                     | Vascular invasion positive | 5 (20)                      | Tumor budding positive      | 3 (12)                      |
| Salvage operation           |                            |                             |                            |                            |                            |                            | Anterior resection          | 1 (4)                       | Low anterior resection      | 9 (36)                      | Intersphincteric resection  | 1 (4)                       | Hartmann operation          | 1 (4)                       | Abdominoperineal resection  | 11 (45)                     | Local excision              | 2 (8)                       |

CEA, carcinoembryonic antigen; BMI, body mass index; ASA, American Society of Anesthesiology; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; MUC, mucinous carcinoma. Data are presented as mean±standard deviation or n (%).

| Table 6. T3 Patients with Recurrence after Local Excision (n=7) |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| Patients Age Sex Pre op TNM stage Pre op CCRT Histologic grade Postop chemotherapy Postop TNM stage Recurrence Recurrence times Salvage operation Follow-up (mo) Outcome Cause of death |
| 1 55 M Stage I T1N0 Yes Stage II T3Nx ADC MD Tegafur/uracil No - - 136 - - Lung meta after 1 yr f/u |
| 2 45 F Stage I T1N0 No Stage II T3Nx ADC MD 5FU +RT No - LAR 156 - - |
| 3 57 F Stage I T1N0 No Stage II T3Nx ADC MD 5FU +RT No - LAR 85 - - |
| 4 83 F Stage II T2N0 No Stage IIa T3N0 ADC MD - Yes 17 month - 47 Expire Lung meta after 1 yr f/u |
| 5 57 M Stage IIIb T3N2 Yes Stage IIa yT3Nx ADC MD - No - ISR 92 - - |
| 6 56 M Stage IIIa T2N1 Yes Stage II T3Nx ADC WD - Yes 13 month L-APR 57 Expire Lung meta after 1 yr f/u |
| 7 76 M Stage II T2N0 Yes Stage IIa yT3Nx ADC MD - No - LAR 72 - - |

LAR, low anterior resection; ISR, intersphincteric resection; ADC, adenocarcinoma; MD, moderately differentiated; APR, abdominoperineal resection; CCRT, concurrent chemoradiation therapy; f/u, follow-up.
AUTHOR CONTRIBUTIONS

Conceptualization: Moon Suk Choi and Jung Wook Huh. Data curation: Moon Suk Choi. Formal analysis: Moon Suk Choi. Investigation: Moon Suk Choi. Methodology: Moon Suk Choi and Jung Wook Huh. Project administration: Moon Suk Choi and Jung Wook Huh. Resources: Jung Wook Huh, Yong Beom Cho, Hee Cheol Kim, Seong Hyeon Yun, and Woo Yong Lee. Software: Moon Suk Choi. Supervision: Moon Suk Choi and Jung Wook Huh. Validation: Moon Suk Choi and Jung Wook Huh. Visualization: Moon Suk Choi. Writing—original draft: Moon Suk Choi. Writing—review & editing: all authors. Approval of final manuscript: all authors.

ORCID iDs

Moon Suk Choi https://orcid.org/0000-0001-5048-1138
Jung Wook Huh https://orcid.org/0000-0002-4485-0184
Jung Kyong Shin https://orcid.org/0000-0002-2298-8799
Yoon Ah Park https://orcid.org/0000-0002-3940-0197
Yong Beom Cho https://orcid.org/0000-0002-9944-4706
Hee Cheol Kim https://orcid.org/0000-0002-1610-5363
Seong Hyeon Yun https://orcid.org/0000-0002-9591-4088
Woo Yong Lee https://orcid.org/0000-0002-9558-9019

REFERENCES

1. Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Buttery LE, Anderson JC, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin 2020;70:145-64.
2. Hur H, Oh CM, Won YJ, Oh JH, Kim NK. Characteristics and survival of Korean patients with colorectal cancer based on data from the Korea central cancer registry data. Ann Coloproctol 2018;34:212-21.
3. Damin DC, Lazzaron AR. Evolving treatment strategies for colorectal cancer: a critical review of current therapeutic options. World J Gastroenterol 2014;20:877-87.
4. Young DO, Kumar AS. Local excision of rectal cancer. Surg Clinic North Am 2017;97:573-85.
5. Nastro P, Beral D, Hartley J, Monson JR. Local excision of rectal cancer: review of literature. Dig Surg 2005;22:6-15.
6. Mellgren A, Sirivongs P, Rothenberger DA, Madoff RD, García-Aguilar J. Is local excision adequate therapy for early rectal cancer? Dis Colon Rectum 2000;43:1064-71.
7. Oh BY, Huh JW, Lee LJ, Park YA, Cho YB, Yun SH, et al. Are we predicting disease progress of the rectal cancer patients without surgery after neoadjuvant chemoradiotherapy? Cancer Res Treat 2018;50:634-55.
8. Smith FM, Reynolds JV, Miller N, Stephens RB, Kennedy MJ. Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy. Eur J Surg Oncol 2006;32:55-64.
9. Bedrosian I, Rodriguez-Bigas MA, Feig B, Hunt KK, Ellis L, Curley SA, et al. Predicting the node-negative mesorectum after preoperative chemoradiation for locally advanced rectal carcinoma. J Gastrointest Surg 2004;8:56-62.
10. Chessin DB, Enker W, Cohen AM, Paty PB, Weiser MR, Saltz L, et al. Complications after preoperative combined modality therapy and radical resection of locally advanced rectal cancer: a 14-year experience from a specialty service. J Am Coll Surg 2005;200:876-82.
11. Hendren SK, O’Connor BI, Liu M, Asano T, Cohen Z, Swallow CJ, et al. Prevalence of male and female sexual dysfunction is high following surgery for rectal cancer. Ann Surg 2005;242:212-23.
12. Bernier L, Balyastnikova S, Tait D, Brown G. Watch-and-wait as a therapeutic strategy in rectal cancer. Curr Colorectal Cancer Rep 2018;14:37-55.
13. São Julião GP, Habr-Gama A, Vailati BB, Araujo SEA, Fernandez LM, Perez RO. New strategies in rectal cancer. Surg Clin North Am 2017;97:587-604.
14. Costa F, Cardoso JM, Louro H, Dias J, Costa L, Rodrigues R, et al. Impact on sexual function of surgical treatment in rectal cancer. Int Braz J Urol 2018;44:141-9.
15. Maeda K, Koide Y, Katsuno H. When is local excision appropriate for ‘early’ rectal cancer? Surg Today 2014;44:2000-14.
16. Sun G, Tang Y, Li X, Meng J, Liang G. Analysis of 11 cases of rectal cancer treated by transanal local excision. World J Surg Oncol 2014;12:202.
17. Lee J, Kelly J, Nassif GJ, Atallah SB, Albert MR, Shridhar R, et al. Chemoradiation and local excision for T2N0 rectal cancer offers equivalent overall survival compared to standard resection: a National Cancer Database analysis. J Gastrointest Surg 2017;21:1666-74.
18. Borschitz T, Wachtlin D, Möhler M, Schmidberger H, Junginger T. Neoadjuvant chemoradiation and local excision for T2-3 rectal cancer. Ann Surg Oncol 2008;15:712-20.
19. Hwang Y, Yoon YS, Bong JW, Choi HY, Song JH, Lee JL, et al. Long-term transanal excision outcomes in patients with T1 rectal cancer: comparative analysis of radical resection. Ann Coloproctol 2019;35:194-201.
20. Nash GM, Weiser MR, Guillem JG, Temple LK, Shia J, Gonen M, et al. Long-term survival after transanal excision of T1 rectal cancer. Dis Colon Rectum 2009;52:577-82.
21. Stitzenberg KB, Sanoff HK, Penn DC, Meyers MO, Tepper JE. Practice patterns and long-term survival for early-stage rectal cancer. J Clin Oncol 2013;31:4276-82.
22. Yun JA, Huh JW, Kim HC, Park YA, Cho YB, Yun SH, et al. Local recurrence after curative resection for rectal carcinoma: the role of surgical resection. Medicine (Baltimore) 2016;95:e3942.
23. Yun HR, Lee LJ, Park JH, Cho YK, Cho YB, Lee WY, et al. Local recurrence after curative resection in patients with colon and rectal cancers. Int J Colorectal Dis 2008;23:1081-7.
24. Yu JJ, Lee H, Park HC, Choi DH, Choi YL, Do IG, et al. Prognostic significance of survivin in rectal cancer patients treated with surgery and postoperative concurrent chemo-radiation therapy. Oncotarget 2016;7:62676-86.
25. Oh BY, Yun HR, Kim SH, Yun SH, Kim HC, Lee WY, et al. Features of late recurrence following transanal local excision for early rectal cancer. Dis Colon Rectum 2015;58:1041-7.
26. Kong JC, Guerra GR, Warrier SK, Ramsay RG, Heriot AG. Outcome and salvage surgery following “watch and wait” for rectal cancer after neoadjuvant therapy: a systematic review. Dis Colon Rectum 2017;60:335-45.
27. Mullaney TG, Lightner AL, Johnston M, Keck J, Watetchow D. ‘Watch and wait’ after chemoradiotherapy for rectal cancer. ANZ J Surg 2018;88:836-41.
28. Paun BC, Cassie S, MacLean AR, Dixon E, Buie WD. Postoperative complications following surgery for rectal cancer. Ann Surg 2010;251:807-18.
29. Law WL, Choi HK, Lee YM, Ho JW. The impact of postoperative complications on long-term outcomes following curative resec-
tion for colorectal cancer. Ann Surg Oncol 2007;14:2559-66.
32. Tanaka K, Kumamoto T, Nojiri K, Matsuyama R, Takeda K, Endo I. Impact of postoperative morbidity on long-term survival after resection for colorectal liver metastases. Ann Surg Oncol 2016;23:929-37.
33. Cai Y, Li Z, Gu X, Fang Y, Xiang J, Chen Z. Prognostic factors associated with locally recurrent rectal cancer following primary surgery (Review). Oncol Lett 2014;7:10-6.
34. De Divitiis C, Nasti G, Montano M, Fisichella R, Iaffaioli RV, Berretta M. Prognostic and predictive response factors in colorectal cancer patients: between hope and reality. World J Gastroenterol 2014;20:15049-59.
35. Suzuki T, Sadahiro S, Tanaka A, Okada K, Saito G, Miyakita H, et al. Outcomes of local excision plus chemoradiotherapy in patients with T1 rectal cancer. Oncology 2018;95:246-50.
36. van Oostendorp SE, Smits LJH, Vroom Y, Detering R, Heymans MW, Moons LMG, et al. Local recurrence after local excision of early rectal cancer: a meta-analysis of completion TME, adjuvant (chemo)radiation, or no additional treatment. Br J Surg 2020;107:1719-30.
37. Huh JW, Park YA, Lee KY, Kim SA, Sohn SK. Recurrences after local excision for early rectal adenocarcinoma. Yonsei Med J 2009;50:704-8.
38. Huh JW, Kim CH, Lim SW, Kim HR, Kim YJ. Early recurrence in patients undergoing curative surgery for colorectal cancer: is it a predictor for poor overall survival? Int J Colorectal Dis 2013;28:1143-9.
39. Yu CS, Yun HR, Shin EJ, Lee KY, Kim NK, Lim SB, et al. Local excision after neoadjuvant chemoradiation therapy in advanced rectal cancer: a national multicenter analysis. Am J Surg 2013;206:482-7.
40. Xu B, Yu L, Zhao LZ, Ma DW. Prognostic factors in the patients with T2N0M0 colorectal cancer. World J Surg Oncol 2016;14:76.
41. Saso K, Myoshi N, Fujino S, Takenaka Y, Takahashi Y, Nishimura J, et al. A novel prognostic prediction model for recurrence in patients with stage II colon cancer after curative resection. Mol Clin Oncol 2018;9:697-701.
42. Ryuk JP, Choi GS, Park JS, Kim HJ, Park SY, Yoon GS, et al. Predictive factors and the prognosis of recurrence of colorectal cancer within 2 years after curative resection. Ann Surg Treat Res 2014;86:143-51.
43. Paty PB, Nash GM, Baron P, Zakowski M, Minsky BD, Blumberg D, et al. Long-term results of local excision for rectal cancer. Ann Surg 2002;236:522-29.